FDA approves prodruge antatine hydrochloric acid release tablets to market

Pharmaceutical SSeptember 10, Plow Pharmaceuticals announced that, recently, its wholly-owned subsidiary Zhejiang Jutai Pharmaceutical Co., Ltdreceived the U.SFood and Drug Administration ("FDA") notice, the company to the U.SFDA to declare the antator of hydrochloric acid amphetamine reprieve of the new drug application (ANDA, that is, the U.Sgeneric drug application) has been approvedhydrochloric acid amphetamine reprieves are suitable for the treatment of severe depression and seasonal affective disorderThe drug was developed by VALEANT INTERNATIONAL BARBADOS SR and was launched in the United States on August 28, 2003At present, the main manufacturers of amphetamine reprieve sepsis tablets in the United States have PAR, TEVA, etc; According to relevant market sales data, the U.Sgeneric drug market for 300 mg of the product was about $120 million in 2018the product was developed by Plo Pharmaceuticals in partnership with Tulex Pharmaceutical CoLtd., Incof the United States, and to date, Plo Pharmaceuticals has invested approximately $1.5 million in research and development on the antatone hydrochloric acid reprieve projectannouncement shows that the hydrochloric acid amphetamine reprieve is the first generic drug approved by the U.SFDA, this time obtained the U.SFDA approval number marks the product of Pro Pharmaceuticals has the qualification to sell in the U.S market, its company to expand the overseas market for generic drugs has a positive role in promoting, but also in line with the company's preparation business international and domestic co-development strategic objectives, the company's future business performance has a certain positive impact Plo Pharmaceuticals will also actively promote the product's readiness to market